A seminal study explored the use of LNP-mediated liver delivery of a siRNA targeted to treat transthyretin (TTR)-induced amyloidosis and was the first LNP-siRNA drug to achieve marketing approval in 2018 (Table 3) [115]. This evidence concerns the gene TTR and amyloidosis.